48.5 D+

Ipamorelin

Also known as: NNC 26-0161

Emerging Research Category 2 Restricted
Research Evidence 32.0/100
Safety Profile 65.0/100

2 Clinical Trials

PHASE2: 2

17 Research Papers

Showing 5 of 17 papers by citation count.

FDA Data

Not FDA-Approved

Ipamorelin has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.

This peptide is classified as FDA Category 2 — it is prohibited from use in compounding pharmacies effective 2024. Obtaining it requires unregulated sources.

Frequently Asked Questions

Is Ipamorelin FDA approved?
No, Ipamorelin is not FDA approved. It is classified as FDA Category 2 and is banned from compounding pharmacies.
How many clinical trials has Ipamorelin been studied in?
Ipamorelin has been studied in 2 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Ipamorelin?
Ipamorelin has a CheckPeptides trust score of 48.5/100 (grade: D+). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026

Quick Facts

Classification
Ghrelin mimetic / GHS
Molecular Weight
711.9 Da
Regulatory Status
N/A

Score Breakdown

Research Evidence 32.0/100
Safety Profile 65.0/100

Evidence Summary

Clinical Trials
2
Research Papers
17
Trust Score
48.5/100
Grade
D+

Compare Peptides

See how Ipamorelin stacks up against similar peptides.

View Comparisons
← Browse all peptides